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Dear Editor,
The recent articles in Clin. Hemorheol. Microcirc. by Jung et al. [1–3], elegantly highlighted the
thrombotic complications that arise in severe coronavirus disease 2019 (COVID-19) and discussed the
role vascular injury and associated hyper inflammation play in bringing about multi-organ failure in
severe disease. Coagulation and venous thromboembolism (VTE) in COVID-19 commonly presents
as deep vein thrombosis (DVT) or pulmonary embolism (PE), and occurs because of inflammation,
blood vessel injury and associated endothelial dysfunction. Likely contributors to this thrombotic
milieu, hitherto little discussed in this COVID-19 pandemic, include Extracellular Vesicles (EVs),
nanosized, cell-derived intercellular communicative vesicles, carrying proteins, bioactive lipids and
miRNAs. Endothelial cell- (EC-) derived EVs (EEVs) are often released because of endothelial injury
[4] and also likely to contribute to this prothrombotic environment. Whilst EVs and VTE in cancer
has been much described, there is a significant knowledge gap concerning EVs and VTE in infectious
disease. This letter considers how, as part of ongoing inflammation, complement may be activated in
SARS-CoV-2 infection and so mediate EV biogenesis. It also assesses the role procoagulant EVs play
in the context of coagulopathy and VTE in COVID-19, and their potential as a prognostic peripheral
blood marker.
During a viral infection, complement activation resulting in membrane attack complex- (C5b-9-)
mediated damage of ECs will bring about the release of EEVs. However, in COVID-19 there are
scarce few preprints describing complement activation [5], and EVs have so far only been mentioned
in the literature as prospective therapeutic tools. A local prothrombotic environment is initiated early in
infection (Fig. A(1)), as Angiotensin-converting enzyme 2 is taken up during Severe acute respiratory
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Fig. A(1). Fig. ExtracellularVesicles and coagulopathy inCOVID-19 SARS-CoV-2 stimulate endocytosis via angiotensis-
converting enzyme 2 (ACE2), initiates the release of proinflammatory cytokines and induces endothelial damage (1).
Complement is activated (2). The resulting Ca2+ influx (3) through deposited C5b-9 (and the SARS-CoV-2 E-protein
Ca2+ channel from ERGIC/ER, not shown) results in a Ca2+ mediated Extracellular Vesicle (EV) release. (4): (i) Weibel
Palade Body exocytosis releasing vWF and CD63+/CD9–/CD81– small EVs; (ii) MultiVesicular Body exocytosis releasing
CD63+/CD9+/CD81+ small EVs; (iii) release of plasma membrane-derived medium EVs carrying coagulation proteins.
In severe COVID-19 (A), where there is increased circulating EV levels, with their known function in coagulopathy, EVs
could play an important role in COVID-related deaths through VTE. Coagulation factors including vWF, and EVs with more
procoagulant morphalogies, as markers of endothelial damage, are released during severe COVID-19 (A) as opposed to those
released during recovery (B).
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syndrome coronavirus 2 (SARS-CoV-2) entry, causing AngII-mediated activation of ECs, platelets and
the release of pro-inflammatory cytokines. Triggering of complement via MBL recognition of damaged
cells, such as ECs (Fig. A(2)), in COVID-19, would generate the Lectin Pathway (LP)/Classical
Pathway (CP) C3 convertase on these cells, Ca2+-mediated release of EVs (Fig. A(3 and 4iii)) and
release of anaphylatoxins, C3a and C5a. Besides recruiting inflammatory cells, C3a/C5a activate ECs
and platelets, promoting proinflammatory cytokine release, coagulation and TF expression [6], as does
MBL-associated Serine Protease (MASP-1) cleavage of Protease-Activated Receptor 4 on ECs [7].
As for SARS-CoV infection, where autoantibodies are formed against cryptic autoantigens, revealed
upon endothelial damage [8], in SARS-CoV-2 infection, where endothelialitis occurs [9], similar
autoantibodies must stimulate CP-mediated complement activation and release of EEVs (Fig. A(2–4)).
With certain viral infections, a transitory increase in pathogenic anti-phospholipid (aPL) antibodies
(APLA) may occur, and if present in COVID-19, result in thrombotic complications. Recently, three
COVID-19 patients with advanced coagulopathy and several cerebral infarctions were found to have
aPL antibodies (anticardiolipin IgA and anti-2-glycoprotein I IgA and IgG) [10]. Although the anti-
2GPI IgG suggests autoantibodies present before COVID-19, it is also likely that the anti-2GPI
component of APLA stimulates EV release from ECs [11], monocytes and platelets. The implication
of antiphospholipid syndrome could explain the coagulopathy, damage to ECs and cerebral ischaemia,
as seen in severe COVID-19.
EVs budding from the EC plasma membrane (medium EVs [mEVs] or microvesicles), expressing E-
selectin (CD62E+), tissue factor (TF+) and other coagulation factors, are known to be raised in patients
with cancer/autoimmune disease and associated VTE [12]. They may also be raised in infectious
diseases as in meningococcal sepsis, where prothrombotic events are common, and where raised TF+-
EVs are derived from monocytes stimulated by endotoxin [13]. In severe COVID-19, which may
lead to acute respiratory distress syndrome, sepsis, septic shock and eventual death, raised TF+-EVs
are also likely. However, besides EVs stimulating thrombosis through TF-dependent mechanisms, in
COVID-19, their procoagulant nature is also due to phosphatidylserine (PtdSer) exposed on the outer
leaflet of the EV lipid bilayer. With exposed negatively charged PtdSer, EEVs and platelet-derived
EVs (PEVs) are able to electrostatically bind various cationic coagulation cascade proteins.
Markers of EC injury and inflammation such as circulating EVs, but also including vWF and Factor
VIII [14], all important contributors to coagulopathy, VTE and increased mortality, are largely raised
in COVID-19 [14]. Besides furthering understanding of pathology and mortality risk in COVID-19,
this capacity to measure EC dysfunction in the systemic vasculature (Fig. A(4)), namely EEVs with
associated surface-bound coagulation factors (prothrombin and factors VII, IX and X) and vWF, could
be used for stratification of COVID-19 severity or clinical prognosis in treatment (comparing dysfunc-
tional endothelium (Fig. A) with convalescent endothelium (Fig. B)). Other EEV phenotypes which
are useful in stratification of thrombotic disorders and could similarly be used in monitoring clinical
progression of COVID-19 include CD31 (PECAM-1)/CD105 (endoglin) markers of myocardial infarc-
tion/acute coronary syndromes and CD54 (ICAM-1)/CD63E (E-selectin)/CD105 (endoglin), markers
of acute ischaemic stroke.
Recently however, some exciting new markers of endothelial injury have emerged. This includes
CD63+ small EVs (sEVs or exosomes), discovered in Weibel-Palade bodies (WPBs) as intraluminal
vesicles [15]. Released from ECs following endothelial injury, during WPB exocytosis, along with vWF
and P-selectin (Fig. A(4i), WPB-sEVs have a unique molecular signature (CD63+/CD9–/CD81–).
Importantly, these WPB-derived sEVs are distinguishable from sEVs (CD63+/CD9+/CD81+) consti-
tutively released through exocytosis of multivesicular bodies (Fig. A(4ii) and B). As WPB-derived
sEVs are only released with vWF upon WPB exocytosis, they could represent an excellent novel
marker of endothelial dysfunction in COVID-19. PEVs already make ideal diagnostic markers of PE;
as specific EVs can be immunoaffinity purified from plasma [16] and generally make optimal diagnos-
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tic tools for non-invasive liquid biopsy [17], EEV phenotypes typical of thrombotic disorders, should
now be used as an important new predictive biomarker monitoring disease progression and therapy
response in COVID-19 patients.
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